The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
February 27th 2024
After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.
Review of the 2022 ACCE Guidelines for Non-Alcoholic Fatty Liver Disease
November 10th 2022The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.
Read More